ZNF7 Knockout cell line (T98G) – Genotype Verified & Ready-to-use

Red cotton OmniCell bank

10000⁺

Gene Knockout Cell Lines

2000⁺

Luc/EGFP/Cas9 Tool Cell Lines

1000⁺

Wild-type Cell Lines

ZNF7 Knockout cell line (T98G)

Copy Product Info

Catalog#

YKO-HA138350

Species

Human

Target Cell Line

T98G

Size

1*10^6

Gene

ZNF7

Storage conditions

Shipped on dry ice; Store in liquid nitrogen

Overview

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZNF7 (zinc finger protein 7) encodes a predicted zinc finger protein with DNA-binding transcription factor activity. It is predicted to bind specific cis-regulatory regions associated with RNA polymerase II and participate in regulation of RNA polymerase II-dependent transcription. ZNF7 is predicted to function primarily in the nucleus, although its specific molecular targets and biological roles remain incompletely characterized.

T98G is a human glioblastoma multiforme cell line derived from a tumor of a 61-year-old male patient. The cells exhibit an indefinite lifespan and anchorage-independent growth properties, while retaining the ability to enter a viable G1-arrested state under serum deprivation conditions. T98G is used as a model for studying glioblastoma biology, cell cycle regulation, tumor growth mechanisms, and therapeutic responses.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

KO Cell Construction Strategy

Adopting Red Cotton CRISPR Gene Editing Designer (www.rc-crispr.com), two sgRNAs targeting the ZNF7 gene are designed to generate a knockout strategy. The two sgRNA sequences are subsequently cloned into the EZ-editor™ vector and introduced into T98G cells via electroporation or lentiviral transduction. Single-cell clones are then generated using the limiting dilution method. Genomic DNA from individual clones is subjected to nucleic acid lysis and PCR amplification using the EZ-editor™ Monoclone Genotype Validation Kit (Cat# YK-MV-1000). The edited loci are further verified by Sanger sequencing to confirm the genotype. After secondary validation and quality confirmation, ZNF7 Knockout cell line (T98G) is expanded and cryopreserved for downstream applications.

Product Overview

ZNF7 Knockout cell line (T98G)

The ZNF7 Knockout cell line (T98G) is generated by targeted disruption of the ZNF7 gene in T98G cells. This cell line is designed to investigate the role of ZNF7 in cellular function and gene regulation, as well as its potential involvement in disease-related pathways.

KO Cell Line

ZNF7 Knockout cell line (T98G)

Gene ID

7553

Catalog

YKO-HA138350

Gene Name

ZNF7

Product Category

Knockout(KO) Cell Line

Gene Information

NCBI

Species

Human

Mycoplasma test

Negative

Cell Morphology

Fibroblast，adherent

Catalog Status

-

Culture method

88%MEM+10%FBS+1%NEAA+1%Sodium Pyruvate 100 mM Solution

Shipping

Cryopreserved Cells shipped in dry ice

Passage ratio

1:2-1:4

Storage Condition

Liquid nitrogen

Quality Control

All KO cell products are tested and confirmed to be free of bacterial, viral, mycoplasma contamination, and other adventitious agents.

Applications

For research use only. Not intended for use in diagnostic, therapeutic, clinical, or other applications.

Key Advantages

Easy to use

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations

High-efficient KO

These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.

Curated cells

Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Quality Control Specifications

1. Bacteria and Fungi Test

None Detected.

2. Mycoplasma test

Negative.

3. Knockout Strategy

Targeted knockout region: EExon 3

Reference Transcript: NM_001330623

Frameshift Mutation Strategy

4. STR Authentication

Download STR Report

Intended use

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use

Unpacking and Storage Instructions

1.

Cell Reception

2.

Unpacking and storage instructions

Handling procedure

1.

Cell Thawing

2.

Cell Passaging

3.

Cell cryopreservation

References

More

FAQ

Q1. How to Contact Support if Issues Arise After Receiving the KO Cells?

If any abnormalities are observed after receiving the cells, please provide the following information based on the stage of use and contact us promptly for assistance:

(1) Issues upon delivery: Please provide photos of the cells at the time of receipt along with a brief description of the issue. We will offer after-sales support accordingly.

(2) Issues after thawing or passaging: Please provide microscopic images of the cells before and after thawing/passaging, along with a detailed description of the experimental procedures. Our technical team will provide professional support.

Q2. What Information Is Required When Reporting KO Cell Product Issues?

Q3. How Should the KO cell Product Be Stored Upon Receipt?

Q4. Shipping Method

Q5. Are the Knockout Cell Lines Stable for Passaging? Is Authentication Provided?